Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes.
Adjuvant therapy
Chemotherapy
Colorectal cancer
Radiotherapy
Survival
Warburg-effect
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
09
12
2022
accepted:
08
01
2023
medline:
23
10
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Tumor location and tumor node metastasis (TNM) stage guide treatment decisions in colorectal cancer (CRC) patients. However, patients with the same disease stage do not benefit equally from adjuvant therapy. Hence, there remains an urgent clinical need to identify prognostic and/or predictive biomarker(s) to personalize treatment decisions. In this exploratory study, we investigated whether our previously defined metabolic Warburg-subtypes can predict which CRC patients might derive survival benefit from adjuvant therapy. Information regarding treatment (surgery only: n = 1451; adjuvant radiotherapy: n = 82; or adjuvant chemotherapy: n = 260) and Warburg-subtype (Warburg-low: n = 485, -moderate: n = 641, or -high: n = 667) was available for 1793 CRC patients from the Netherlands Cohort Study (NLCS). Kaplan-Meier curves and Cox regression models were used to investigate survival benefit from adjuvant therapy compared to surgery-only for the different Warburg-subtypes. Patients with Warburg-moderate CRC (HR Our results suggest that Warburg-subtypes may predict survival benefit from adjuvant therapy in CRC patients. A survival benefit from adjuvant therapy was observed for patients with Warburg-moderate and possibly Warburg-high CRC, but not for patients with Warburg-low CRC. Future prospective studies are necessary to validate our findings.
Identifiants
pubmed: 36723668
doi: 10.1007/s00432-023-04581-w
pii: 10.1007/s00432-023-04581-w
pmc: PMC10356897
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6271-6282Subventions
Organisme : KWF Kankerbestrijding
ID : 11044
Informations de copyright
© 2023. The Author(s).
Références
Eur J Cancer. 2001 Jan;37(2):204-9
pubmed: 11166147
BMC Syst Biol. 2014 Dec 18;8:134
pubmed: 25518943
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Epidemiol Biomarkers Prev. 2022 Mar 01;31(3):633-646
pubmed: 34933957
Int J Epidemiol. 1990 Sep;19(3):553-8
pubmed: 2262247
Eur J Surg Oncol. 2008 Dec;34(12):1316-21
pubmed: 18313881
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
Int J Cancer. 2022 Jun 1;150(11):1812-1824
pubmed: 35064924
Front Oncol. 2021 Sep 03;11:698023
pubmed: 34540667
J Exp Clin Cancer Res. 2022 Jan 8;41(1):15
pubmed: 34998404
J Pathol. 2018 Sep;246 Suppl 1:S1-S46
pubmed: 30188613
Biochem Soc Trans. 2016 Oct 15;44(5):1499-1505
pubmed: 27911732
Cancer Sci. 2020 Feb;111(2):658-666
pubmed: 31823471
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1867-1874
pubmed: 34272264
Stem Cell Reports. 2018 Dec 11;11(6):1506-1522
pubmed: 30449704
Arch Iran Med. 2012 Aug;15(8):508-16
pubmed: 22827790
J Clin Epidemiol. 1990;43(3):285-95
pubmed: 2313318
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Front Oncol. 2020 Mar 06;10:281
pubmed: 32211323
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
Ann Oncol. 2010 Nov;21(11):2206-2212
pubmed: 20439339
Biochem Biophys Res Commun. 2016 Apr 22;473(1):174-180
pubmed: 27012213
Clin Cancer Res. 2015 Jun 15;21(12):2870-9
pubmed: 25779952
Oncotarget. 2015 Dec 8;6(39):41706-21
pubmed: 26527315
World J Gastroenterol. 2018 Sep 14;24(34):3834-3848
pubmed: 30228778
Trends Cell Biol. 2018 Mar;28(3):201-212
pubmed: 29229182
J Pathol Clin Res. 2022 Mar;8(2):169-180
pubmed: 34791830
Int J Mol Sci. 2017 Oct 24;18(10):
pubmed: 29064420
Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45
pubmed: 17684528
Jpn Dent Sci Rev. 2018 Feb;54(1):8-21
pubmed: 29628997
Clin Gastroenterol Hepatol. 2016 May;14(5):651-8
pubmed: 26872400
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):1-6
pubmed: 28065746
Semin Cell Dev Biol. 2012 Jun;23(4):352-61
pubmed: 22406683
J Natl Cancer Inst. 2022 Apr 11;114(4):503-516
pubmed: 34077519
Oncotarget. 2017 Feb 21;8(8):14133-14146
pubmed: 27823965
Ann Oncol. 2019 Apr 1;30(4):520-527
pubmed: 30796810
Front Oncol. 2018 Nov 02;8:500
pubmed: 30456204
Curr Treat Options Oncol. 2015 Jul;16(7):30
pubmed: 26031544
Semin Cell Dev Biol. 2017 Apr;64:107-115
pubmed: 27578007
Theranostics. 2018 Oct 22;8(19):5259-5275
pubmed: 30555545
J Pathol. 2010 Aug;221(4):361-2
pubmed: 20593484